Big ideas attract big funding
By Rob Clancy, staff writer
Hudson Institute researchers have featured prominently among the latest recipients of 2022 NHMRC Ideas Grants.
Our researchers have been awarded $6.34 million for five new NHMRC Ideas Grants to work on influenza, endometriosis, autoimmune diseases, post-caesarean care for newborns and non-genetic inheritance in health and disease.
NHMRC Ideas Grants
Understanding non-genetic inheritance in health and disease
Associated Professor Patrick Western
Eggs provide genetic and non-genetic (epigenetic) information that is critical for offspring development. While it is understood how genes transmit instructions that regulate offspring development, epigenetic inheritance is poorly understood. This project will determine how an essential epigenetic mechanism acting in eggs controls formation of tissues in offspring and grand-offspring and how dysregulation of this mechanism results in disease. Outcomes will help understand disease inheritance.
Reducing the burden of respiratory distress after caesarean delivery
Dr Kelly Crossley
Compared with vaginally born babies, babies born at term by caesarean section have a higher risk of needing intensive care due to breathing problems soon after birth. The team have recently made a major break-through in understanding why, and this project will provide the additional information required to identify effective treatments for these otherwise healthy newborns. Ultimately this research will identify approaches and treatments that will reduce the risk or severity of newborn breathing problems.
Therapeutic targeting of TLR7 in autoimmunity
Associate Professor Michael Gantier
Autoimmune diseases affect approximately five per cent of Australians and are driven by autoantibodies. While treatments are available to limit disease progression and morbidity, these are non-curative and have numerous side-effects. The team propose an innovative approach to tackle the management of autoimmunity by targeting how auto-antibodies are generated. A new class of highly-specific therapeutics has been generated that have the potential to help management of diverse autoimmune conditions.
Harnessing the protective effects of Interferon epsilon as a therapeutic target for endometriosis
Dr Fiona Cousins
Endometriosis is a chronic, debilitating condition that affects one in nine menstruators. People with the disease have limited treatment options and there is no cure. A defective immune response is one of the causes of the disease. This project aims to investigate a new immunomodulator, interferon epsilon (IFNε), which may exert protective effects against the development of endometriosis. The team will investigate whether IFNε can be used as an innovative treatment for endometriosis.
Targeting pyroptosis to limit the severity of influenza virus infections
Associate Professor Michelle Tate
Highly pathogenic influenza A virus infections are associated with high mortality rates. To facilitate the development of improved treatments for severe IAV infections, this project will advance the fundamental knowledge of mechanisms by which the host and virus interact and elucidate how the host’s immune system can be therapeutically modulated to limit disease severity. These studies are crucial to prepare for the next pandemic.
In this article
-
Professor Patrick Western
Germ Cell Development and Epigenetics -
Dr Kelly Crossley
Fetal and Neonatal Health -
Associate Professor Michael Gantier
Nucleic Acids and Innate Immunity -
Dr Fiona Cousins
Endometrial Stem Cell Biology -
Associate Professor Michelle Tate
Viral Immunity and Immunopathology -
Professor Ron Firestein
Cancer Genetics and Functional Genomics
About Hudson Institute
Hudson Institute’ s research programs deliver in three areas of medical need – inflammation, cancer, women’s and newborn health. More
Hudson News
Get the inside view on discoveries and patient stories
“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”